Short answer
Anteris Technologies Global Corp. (AVR) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 financial results for quarter ended September 30, 2026.
Anteris Technologies Global Corp. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Form 10-Q filed with ASX on November 10, 2026, U.S. time
- Unaudited historical financial information available in Exhibits 99.1 and 99.2
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 reporting period covered by the filed Form 10-Q and ASX quarterly disclosure
- Related-party payments totaled US$576,000, including executive salaries and non-executive director fees
- All related-party payments flowed through operating activities, with none included in investing activities
- Investors should review the Form 10-Q and November 11, 2026 results announcement for operating and financial performance
Item EX-99.2 · Exhibit EX-99.2
- Q3 2026 operating cash outflows $22.9M, highlighting substantial funding needs during pivotal-trial execution
- R&D expense $21.3M, driven by PARADIGM enrollment, manufacturing scale-up, quality validation and expanded clinical staffing
- PARADIGM Trial expanding across the U.S., Canada and Europe, with Germany and Australia added after quarter-end
- Northcross facility occupancy expands DurAVR THV and ComASUR production capacity ahead of potential commercialization
- Trial targets approximately 1,000 patients, testing DurAVR against commercial TAVRs on a one-year composite endpoint
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Anteris Technologies Global Corp. 8-K filings
Get the next AVR 8-K as it lands
Follow AVR for push alerts, or ask the research agent what this filing means.